Oppenheimer Thinks TherapeuticsMD’s Stock is Going to Recover

By Carrie Williams

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on TherapeuticsMD (NYSE MKT: TXMD), with a price target of $14. The company’s shares opened today at $4.76, close to its 52-week low of $4.34.

Olson noted:

“Investors wondered if Bijuva was a trick or treat as shares sold off following FDA approval of TXMD’s 3rd new drug in 2018. Bijuva becomes the first and only bio-identical combination of estradiol with progesterone approved by the FDA for the treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause in women with a uterus. We heard investor concerns about Bijuva dose, launch timing which is later than expected by some, label and potential launch trajectory. We view Bijuva as instrumental to TXMD’s industry-leading Women’s Health portfolio and consider today’s news a clear win for patients and shareholders. We update our model to reflect today’s news and maintain our Outperform rating with $14 PT. Details inside.”

According to TipRanks.com, Olson has 0 stars on 0-5 star ranking scale with an average return of -6.4% and a 35.3% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Eiger Biopharmaceuticals, and Conatus Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for TherapeuticsMD with a $20.33 average price target, which is a 327.1% upside from current levels. In a report issued on October 14, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $27 price target.

.

See today’s analyst top recommended stocks >>

Based on TherapeuticsMD’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $33.22 million. In comparison, last year the company had a GAAP net loss of $14.66 million.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TXMD in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.